Compare AMWD & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWD | LBRX |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.8M | 850.5M |
| IPO Year | 1995 | N/A |
| Metric | AMWD | LBRX |
|---|---|---|
| Price | $38.86 | $28.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $59.50 | $46.60 |
| AVG Volume (30 Days) | ★ 259.6K | 127.7K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,709,585,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.29 | $13.40 |
| 52 Week High | $72.16 | $33.47 |
| Indicator | AMWD | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 43.90 |
| Support Level | $36.48 | $22.39 |
| Resistance Level | $42.58 | $33.47 |
| Average True Range (ATR) | 2.02 | 1.66 |
| MACD | 0.07 | -0.67 |
| Stochastic Oscillator | 58.11 | 25.25 |
American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.